Classifications

• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07D—HETEROCYCLIC COMPOUNDS
  • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
  • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
  • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
  • C07D231/12—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P11/00—Drugs for disorders of the respiratory system
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P13/00—Drugs for disorders of the urinary system
  • A61P13/12—Drugs for disorders of the urinary system of the kidneys
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P17/00—Drugs for dermatological disorders
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P17/00—Drugs for dermatological disorders
  • A61P17/06—Antipsoriatics
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P19/00—Drugs for skeletal disorders
  • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P19/00—Drugs for skeletal disorders
  • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
  • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P25/00—Drugs for disorders of the nervous system
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P25/00—Drugs for disorders of the nervous system
  • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
  • A61P29/02—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] without antiinflammatory effect
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P3/00—Drugs for disorders of the metabolism
  • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
  • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P37/00—Drugs for immunological or allergic disorders
  • A61P37/02—Immunomodulators
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P9/00—Drugs for disorders of the cardiovascular system
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P9/00—Drugs for disorders of the cardiovascular system
  • A61P9/08—Vasodilators for multiple indications
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P9/00—Drugs for disorders of the cardiovascular system
  • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07D—HETEROCYCLIC COMPOUNDS
  • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
  • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
  • C07D207/30—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
  • C07D207/34—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07D—HETEROCYCLIC COMPOUNDS
  • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
  • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
  • C07D233/56—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07D—HETEROCYCLIC COMPOUNDS
  • C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
  • C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
  • C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07D—HETEROCYCLIC COMPOUNDS
  • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
  • C07D307/02—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
  • C07D307/34—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
  • C07D307/56—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
  • C07D307/68—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07D—HETEROCYCLIC COMPOUNDS
  • C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
  • C07D333/02—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
  • C07D333/04—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
  • C07D333/26—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
  • C07D333/38—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07D—HETEROCYCLIC COMPOUNDS
  • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
  • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
  • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07D—HETEROCYCLIC COMPOUNDS
  • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
  • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
  • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07D—HETEROCYCLIC COMPOUNDS
  • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
  • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
  • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links

Definitions

• Aromatic Heterocyclic Compounds as Anti-inflammatory Agents are Aromatic Heterocyclic Compounds as Anti-inflammatory Agents
• This invention relates to novel aromatic heterocyclic compounds of formula (I):
• Ar,, Ar 2 , X, L and Q are defined below, which inhibit production of cytokines involved in inflammatory processes and are thus useful for treating diseases and pathological conditions involving inflammation such as chronic inflammatory disease.
• This invention also relates to processes for preparing these compounds and to pharmaceutical compositions comprising these compounds.
• TNF Tumor necrosis factor
• IL-1 interleukin-1
• Elevated levels of proinflammatory cytokines are also associated with a number of diseases of auto immunity such as toxic shock syndrome, rheumatoid arthritis, osteoarthritis, diabetes and inflammatory bowel disease (Dinarello, C.A., et al. , 1984, Rev. Infect. Disease 6:51). In these diseases, chronic elevation of inflammation exacerbates or causes much of the pathophysiology observed. For example, rheumatoid synovial tissue becomes invaded with inflammatory cells that result in destruction to cartilage and bone (Koch, A.E. , et al., 1995, J. Invest. Med. 43: 28-38).
• TNF proinflammatory cytokines
• IL-l ⁇ proinflammatory cytokines
• TNF ⁇ also referred to in its secreted cell-free form termed TNF ⁇
• IL-l ⁇ proinflammatory cytokines
• Efficacy has been demonstrated with a monoclonal antibody directed against TNF ⁇ in a number of autoimmune diseases (Heath, P., "CDP571 : An Engineered Human IgG4 Anti- TNF ⁇ Antibody” IBC Meeting on Cytokine Antagonists, Philadelphia, PA, April 24-5, 1997). These include the treatment of rheumatoid arthritis, Crohn's disease and ulcerative colitis (Rankin, E.C.C. , et al.
• the monoclonal antibody is thought to function by binding to both soluble TNF ⁇ and to membrane bound TNF.
• a soluble TNF ⁇ receptor has been engineered that interacts with TNF ⁇ . The approach is similar to that described above for the monoclonal antibodies directed against TNF ⁇ ; both agents bind to soluble TNF ⁇ , thus reducing its concentration.
• Enbrel Immunex, Seattle, WA
• Another version of the TNF ⁇ receptor, Ro 45-2081 has demonstrated efficacy in various animal models of allergic lung inflammation and acute lung injury.
• Ro 45-2081 is a recombinant chimeric molecule constructed from the soluble 55 kDa human TNF receptor fused to the hinge region of the heavy chain IgGl gene and expressed in eukaryotic cells (Renzetti, et al., 1997, Inflamm. Res. 46: S143).
• IL-1 has been implicated as an immunological effector molecule in a large number of disease processes.
• IL-1 receptor antagonist (IL-lra) had been examined in human clinical trials. Efficacy has been demonstrated for the treatment of rheumatoid arthritis (Antril, Amgen). In a phase III human clinical trial IL-lra reduced the mortality rate in patients with septic shock syndrome (Dinarello, 1995, Nutrution 11, 492). Osteoarthritis is a slow progressive disease characterized by destruction of the articular cartilage. IL-1 is detected in synovial fluid and in the cartilage matrix of osteoarthritic joints.
• Antagonists of IL-1 have been shown to diminish the degradation of cartilage matrix components in a variety of experimental models of arthritis (Chevalier, 1997, Biomed Pharmacother. 51, 58).
• Nitric oxide (NO) is a mediator of cardiovascular homeostasis, neurotransmission and immune function; recently it has been shown to have important effects in the modulation of bone remodeling.
• Cytokines such as IL-1 and TNF are potent stimulators of NO production.
• NO is an important regulatory molecule in bone with effects on cells of the osteoblast and osteoclast lineage (Evans, et al, 1996, J Bone Miner Res. 11, 300). The promotion of beta-cell destruction leading to insulin dependent diabetes mellitis shows dependence on IL-1.
• IL-1 can effect this process by controlling the level of both cyclooxygenase II and inducible nitric oxide synthetase expression (McDaniel et al, 1996, Proc Soc Exp Biol Med. 211, 24).
• Inhibitors of cytokine production are expected to block inducible cyclooxygenase (COX-2) expression.
• COX-2 expression has been shown to be increased by cytokines and it is believed to be the isoform of cyclooxygenase responsible for inflammation (M.K. O'Banion et ⁇ b , Proc. Natl. Acad. Sci. U.S.A, 1992, 89, 4888.)
• inhibitors of cytokines such as IL-1 would be expected to exhibit efficacy against those disorders currently treated with COX inhibitors such as the familiar NSAIDs. These disorders include acute and chronic pain as well as symptoms of inflammation and cardiovascular disease.
• IBD active inflammatory bowel disease
• a mucosal imbalance of intestinal IL-1 and IL-lra is present in patients with IBD. Insufficient production of endogenous IL-lra may contribute to the pathogenesis of IBD (Cominelli, et al., 1996, Aliment Pharmacol Ther. 10, 49).
• Alzheimer disease is characterized by the presence of beta-amyloid protein deposits, neurofibrillary tangles and cholinergic dysfunction throughout the hippocampal region. The structural and metabolic damage found in Alzheimer disease is possibly due to a sustained elevation of IL-1 (Holden, et al., 1995, Med Hypootheses 45, 559).
• IL-1 A role for IL-1 in the pathogenesis of human immunodeficiency virus (HIV) has been identified.
• HIV human immunodeficiency virus
• IL-lra showed a clear relationship to acute inflammatory events as well as to the different disease stages in the pathophysiology of HIV infection (Kreuzer, et al., 1997, Clin Exp Immunol. 109, 54).
• IL-1 and TNF are both involved in periodontal disease. The destructive process associated with periodontal disease may be due to a disregulation of both IL-1 and TNF (Howells, 1995, Oral Dis. 1, 266).
• TNF ⁇ and IL-l ⁇ are also important mediators of septic shock and associated cardiopulmonary dysfunction, acute respiratory distress syndrome (ARDS) and multiple organ failure.
• TNF ⁇ has also been implicated in cachexia and muscle degradation, associated with HIV infection (Lahdiverta et al. , 1988, Amer. J. Med., 85, 289). Obesity is associated with an increase incidence of infection, diabetes and cardiovascular disease. Abnormalities in TNF ⁇ expression have been noted for each of the above conditions (Lrissada, et al., 1998, FASEB J. 12, 57). It has been proposed that elevated levels of TNF ⁇ are involved in other eating related disorders such as anorexia and bulimia nervosa.
• Pathophysiological parallels are drawn between anorexia nervosa and cancer cachexia (Holden, et al., 1996, Med Hypotheses 47, 423).
• An inhibitor of TNF ⁇ production, HU-211 was shown to improve the outcome of closed brain injury in an experimental model (Shohami, et al, 1997 , J Neuroimmunol. 72, 169).
• Atherosclerosis is known to have an inflammatory component and cytokines such as IL-1 and TNF have been suggested to promote the disease.
• an IL-1 receptor antagonist was shown to inhibit fatty streak formation (Elhage et al., 1998, Circulation, 97,
• iNOS inducible nitric oxide synthetase
• IL-1 has also been shown to induce uveitis in rats which could be inhibited with IL- 1 blockers.
• Cytokines including IL-1, TNF and GM-CSF have been shown to stimulate proliferation of acute myelogenous leukemia blasts (Bruserud, 1996, Leukemia Res. 20, 65).
• IL-1 was shown to be essential for the development of both irritant and allergic contact dermatitis. Epicutaneous sensitization can be prevented by the administration of an anti- IL-1 monoclonal antibody before epicutaneous application of an allergen (Muller, et al., 1996, Am J Contact Dermat. 7, 177).
• IL-1 knock out mice Data obtained from IL-1 knock out mice indicates the critical involvement in fever for this cytokine (Kluger et al., 1998, Clin Exp Pharmacol Physiol. 25, 141).
• a variety of cytokines including TNF, IL-1, IL-6 and IL-8 initiate the acute-phase reaction which is stereotyped in fever, malaise, myalgia, headaches, cellular hypermetabolism and multiple endocrine and enzyme responses (Beisel, 1995, Am J Clin Nutr. 62, 813).
• the production of these inflammatory cytokines rapidly follows trauma or pathogenic organism invasion.
• IL-8 correlates with influx of neutrophils into sites of inflammation or injury. Blocking antibodies against IL-8 have demonstrated a role for IL-8 in the neutrophil associated tissue injury in acute inflammation (Harada et al, 1996, Molecular Medicine Today 2, 482).
• an inhibitor of IL-8 production may be useful in the treatment of diseases mediated predominantly by neutrophils such as stroke and myocardial infarction, alone or following thrombolytic therapy, thermal injury, adult respiratory distress syndrome (ARDS), multiple organ injury secondary to trauma, acute glomerulonephritis, dermatoses with acute inflammatory components, acute purulent meningitis or other central nervous system disorders, hemodialysis, leukopherisis, granulocyte transfusion associated syndromes, and necrotizing entrerocolitis.
• neutrophils such as stroke and myocardial infarction, alone or following thrombolytic therapy, thermal injury, adult respiratory distress syndrome (ARDS), multiple organ injury secondary to trauma, acute glomerulonephritis, dermatoses with acute inflammatory components, acute purulent meningitis or other central nervous system disorders, hemodialysis, leukopherisis, granulocyte transfusion associated syndromes, and necrotizing entrerocolitis.
• Rhinovirus triggers the production of various proinflammatory cytokines, predominantly IL-8, which results in symptomatic illnesses such as acute rhinitis (Winther et b, 1998, Am J Rhinol. 12, 17).
• IL-8 diseases that are effected by IL-8 include myocardial ischemia and reperfusion, inflammatory bowel disease and many others.
• IL-6 The proinflammatory cytokine IL-6 has been implicated with the acute phase response.
• IL-6 is a growth factor in a number in oncological diseases including multiple myeloma and related plasma cell dyscrasias (Treon, et al., 1998, Current Opinion in Hematology 5: 42). It has also been shown to be an important mediator of inflammation within the central nervous system. Elevated levels of IL-6 are found in several neurological disorders including AIDS dememtia complex, Alzheimer's disease, multiple sclerosis, systemic lupus erythematosus, CNS trauma and viral and bacterial meningitis (Gruol, et al. , 1997, Molecular Neurobiology 15: 307).
• IL-6 also plays a significant role in osteoporosis. In murine models it has been shown to effect bone resorption and to induce osteoclast activity (Ershler et al, 1997, Development and Comparative Immunol. 21: 487). Marked cytokine differences, such as IL-6 levels, exist in vivo between osteoclasts of normal bone and bone from patients with Paget's disease (Mills, et al, 1997, Calcif Tissue Int. 61, 16). A number of cytokines have been shown to be involved in cancer cachexia. The severity of key parameters of cachexia can be reduced by treatment with anti IL-6 antibodies or with IL-6 receptor antagonists (Strassmann, et al, 1995, Cytokins Mol Ther.
• IL-6 and IFN alpha as key factors in both symptom formation and in host defense
• Overexpression of IL-6 has been implicated in the pathology of a number of diseases including multiple myeloma, rheumatoid arthritis, Castleman's disease, psoriasis and post-menopausal osteoporosis (Simpson, et al, 1997, Protein Sci. 6, 929).
• Compounds that interfered with the production of cytokines including IL-6, and TNF were effective in blocking a passive cutaneous anaphylaxis in mice (Scholz et al, 1998, J. Med. Chem., 41, 1050).
• GM-CSF is another proinflammatory cytokine with relevance to a number of therapeutic diseases. It influences not only proliferation and differentiation of stem cells but also regulates several other cells involved in acute and chronic inflammation. Treatment with GM-CSF has been attempted in a number of disease states including burn- wound healing, skin-graft resolution as well as cytostatic and radiotherapy induced mucositis (Masucci, 1996, Medical Oncology 13: 149). GM- CSF also appears to play a role in the replication of human immunodeficiency virus (HIV) in cells of macrophage lineage with relevance to AIDS therapy (Crowe et al, 1997, Journal of Leukocyte Biology 62, 41). Bronchial asthma is characterised by an inflammatory process in lungs. Involved cytokines include GM-CSF amongst others (Lee, 1998, J R Coll Physicians Lond 32, 56).
• HIV human immunodeficiency virus
• Interferon ⁇ has been implicated in a number of diseases. It has been associated with increased collagen deposition that is a central histopathological feature of graft- versus-host disease (Parkman, 1998, Curr Opin Hematol. 5, 22). Following kidney transplantation, a patient was diagnosed with acute myelogenous leukemia. Retrospective analysis of peripheral blood cytokines revealed elevated levels of GM-CSF and IFN ⁇ . These elevated levels coincided with a rise in peripheral blood white cell count (Burke, et al, 1995, Leuk Lymphoma. 19, 173).
• IFN ⁇ insulin-dependent diabetes
• MS multiple sclerosis
• AIDS dementia complex Alzheimer's disease
• cytokines such as TNF, IL-1 and IFN ⁇ . These cytokines are thought to be involved in promoting apoptosis or programmed cell death of the surrounding vascular smooth muscle cells resulting in the atherosclerotic lesions (Geng, 1997, Heart Vessels Suppl 12, 76). Allergic subjects produce mRNA specific for IFN ⁇ following challenge with Vespula venom (Bonay, et al, 1997, Clin Exp Immunol 109, 342).
• cytokines including IFN ⁇ has been shown to increase following a delayed type hypersensitivity reaction thus indicating a role for IFN ⁇ in atopic dermatitis (Szepietowski, et al, 1997, Br J Dermatol. 137, 195). Histopathologic and immunohistologic studies were performed in cases of fatal cerebral malaria. Evidence for elevated IFN ⁇ amongst other cytokines was observed indicating a role in this disease (Udomsangpetch et al, 1997, Am J Trop Med Hyg. 57, 501). The importance of free radical species in the pathogenesis of various infectious diseases has been established.
• the nitric oxide synthesis pathway is activated in response to infection with certain viruses via the induction of proinflammatory cytokines such as IFN ⁇ (Akaike, et al, 1998, Proc Soc Exp Biol Med. 217, 64).
• proinflammatory cytokines such as IFN ⁇
• Patients, chronically infected with hepatitis B virus (HBV) can develop cirrhosis and hepatocellular carcinoma.
• Viral gene expression and replication in HBV transgenic mice can be suppressed by a post-transcriptional mechanism mediated by IFN ⁇ , TNF and IL-2 (Chisari, et al, 1995, Springer Semin Immunopathol. 17, 261).
• IFN ⁇ can selectively inhibit cytokine induced bone resorption.
• NO nitric oxide
• NO is an important vasodilator and convincing evidence exists for its role in cardiovascular shock (Kilbourn, et al, 1997, Dis Mon. 43, 277).
• IFN ⁇ is required for progression of chronic intestinal inflammation in such diseases as Crohn's disease and inflammatory bowel disease (IBD) presumably through the intermediacy of CD4+ lymphocytes probably of the TH1 phenotype (Sartor 1996, Aliment Pharmacol Ther. 10 Suppl 2, 43).
• An elevated level of serum IgE is associated with various atopic diseases such as bronchial asthma and atopic dermatitis.
• the level of IFN ⁇ was negatively correlated with serum IgE suggesting a role for IFN ⁇ in atopic patients (Teramoto et al, 1998, Clin Exp Allergy 28, 74).
• WO 98/52558 discloses heteroaryl urea compounds which are indicated to be useful in treating cytokine mediated diseases.
• U.S. Pat. No. 5,162,360 discloses N-substituted aryl-N '-heterocyclic substituted urea compounds which are described as being useful for treating hypercholesterolemia and atheroclerosis.
• the present invention is directed to compounds of the formula (I):
• Ar j is a heterocyclic group selected from the group consisting of pyrrole, pyrrolidine, pyrazole, imidazole, oxazole, thiazole, furan, and thiophene; and wherein Ar ! may be substituted by one or more R 1 ? R 2 or R 3 ;
• Ar 2 is:
• L is a linking group of: a C 0 saturated or unsaturated branched or unbranched carbon chain; wherein one or more methylene groups are optionally independently replaced by O,N or S; wherein said linking group is optionally independently substituted with 0-2 oxo groups or one or more C M branched or unbranched alkyl which may be substituted by one or more halogen atoms;
• Q is selected from the group consisting of:
• tetrahydropyran tetrahydrofuran, 1,3-dioxolanone, 1,3-dioxanone, 1,4-dioxane, morpholine, thiomorpholine, thiomorpholine sulfoxide, piperidine, piperidinone, tetrahydropyrimidone, cyclohexanone, cyclohexanol, pentamethylene sulfide, pentamethylene sulfoxide, pentamethylene sulfone, tetramethylene sulfide, tetramethylene sulfoxide and tetramethylene sulfone which are optionally substituted with one to three groups selected from the group consisting of C,.
• C 3 _ ⁇ o branched alkenyl which may optionally be partially or fully halogenated, and which optionally be substituted with one to three C ⁇ _ 5 branched or unbranched alkyl, phenyl, naphthyl or heterocyclyl groups, with each such heterocyclic group being independently selected from the group consisting of pyridinyl, pyrimidinyl, pyrazinyl, pyridazinyl, pyrrolyl, imidazolyl, pyrazolyl, thienyl, furyl, isoxazolyl and isothiazolyl, and each such phenyl, naphthyl or heterocyclyl group being substituted with 0 to 5 groups selected from halogen, C ⁇ _ 6 branched or unbranched alkyl which is optionally partially or fully halogenated, cyclopropyl, cyclobutyl, cyclopentanyl, cyclohexanyl, cycloheptanyl
• R 2 is selected from the group consisting of:
• R 3 is : halogen, -COOR 4 , -CN, -CONR ⁇ or -CH 2 NHR 7 ;
• R 4 is H or C,. 4 -alkyl
• R 5 is hydrogen; Rg is methyl;
• R 7 is hydrogen, methyl or -C(O)R 8 ;
• R 8 is hydrogen or methyl optionally substituted by N(Ro) 2 or COOR ⁇ ;
• Ro is C ⁇ _ 6 -alkyl
• Rio is selected from the group consisting of: a C w branched or unbranched alkyl which may optionally be partially or fully halogenated, acetyl, aroyl, C]_ 4 branched or unbranched alkoxy which may optionally be partially or fully halogenated, halogen, methoxycarbonyl and phenylsulfonyl;
• n 0, 1 or 2;
• X is O (oxygen) or S (sulfur) and pharmaceutically acceptable derivatives thereof.
• a preferred subgeneric aspect of the invention comprises compounds of the formula(I) wherein A ⁇ is selected from the group consisting of:
• Ar 2 is naphthyl, tetrahydronaphthyl, indanyl or indenyl.
• An even more preferred subgeneric aspect of the invention comprises compounds of the formula(I) wherein Ar 2 is naphthyl.
• a yet more preferred subgeneric aspect of the invention comprises compounds of the formula (I), as described in the immediate previous paragraph, wherein: Ar 2 is 1 -naphthyl;
• L is C ⁇ _ 6 saturated or unsaturated branched or unbranched carbon chain wherein one or more methylene groups are optionally independently replaced by O,N or S; wherein said linking group is optionally independently substituted with 0-2 oxo groups and one or more C M branched or unbranched alkyl which may be substituted by one or more halogen atoms;
• R is C ⁇ _ 4 alkyl branched or unbranched, cyclopropyl or cyclohexyl which may optionally be partially or fully halogenated and which may optionally be substituted with one to three C ⁇ _ 3 alkyl groups; and R 3 is -COOR 4 , -CN, -CONR 5 R 6 or -CH 2 NHR 7 .
• a further preferred subgeneric aspect of the invention comprises compounds of the formula (I), wherein Ari is 5-tert-butyl-3-thienyl or 5-tert-butyl-3-pyrrolyl.
• a still yet further preferred subgeneric aspect of the invention comprises compounds of the formula (I), as described in the immediate previous paragraph, wherein L is C ⁇ _ 5 saturated carbon chain wherein one or more methylene groups are optionally independently replaced by O,N or S; and wherein said linking group is optionally independently substituted with 0-2 oxo groups and one or more C 4 branched or unbranched alkyl which may be substituted by one or more halogen atoms and X is O.
• L is propoxy, ethoxy, methoxy, methyl, propyl, C 3 . 5 acetylene or methylamino each being optionally substituted are described herein.
• Any compounds of this invention containing one or more asymmetric carbon atoms may occur as racemates and racemic mixtures, single enantiomers, diastereomeric mixtures and individual diastereomers. All such isomeric forms of these compounds are expressly included in the present invention.
• Each stereogenic carbon may be in the R or S configuration, or a combination of configurations.
• Some of the compounds of formula (I) can exist in more than one tautomeric form.
• the invention includes all such tautomers.
• C,. 6 alkoxy is a C,. 6 alkyl with a terminal oxygen, such as methoxy, ethoxy, propoxy, pentoxy and hexoxy. All alkyl groups shall be understood as being branched or unbranched unless otherwise specified. Other more specific definitions are as follows:
• aroyl as used in the present specification shall be understood to mean “benzoyl” or “naphthoyl”.
• halogen as used in the present specification shall be understood to mean bromine, chlorine, fluorine or iodine.
• the compounds of the invention are only those which are contemplated to be 'chemically stable' as will be appreciated by those skilled in the art.
• a compound which would have a 'dangling valency', or a 'carbanion' are not compounds contemplated by the invention.
• the invention includes pharmaceutically acceptable derivatives of compounds of formula (I).
• a "pharmaceutically acceptable derivative” refers to any pharmaceutically acceptable salt or ester of a compound of this invention, or any other compound which, upon administration to a patient, is capable of providing (directly or indirectly) a compound of this invention, a pharmacologically active metabolite or pharmacologically active residue thereof.
• Pharmaceutically acceptable salts of the compounds of this invention include those derived from pharmaceutically acceptable inorganic and organic acids and bases.
• suitable acids include hydrochloric, hydrobromic, sulfuric, nitric, perchloric, fumaric, maleic, phosphoric, glycolic, lactic, salicylic, succinic, toluene-p- sulfuric, tartaric, acetic, citric, methanesulfonic, formic, benzoic, malonic, naphthalene-2-sulfuric and benzenesulfonic acids.
• Salts derived from appropriate bases include alkali metal (e.g., sodium), alkaline earth metal (e.g., magnesium), ammonium and N-(C j -C alkyl) + salts.
• the compounds of this invention include prodrugs of compounds of the formula (I).
• Prodrugs include those compounds that, upon simple chemical transformation, are modified to produce a compound of formula (I).
• Simple chemical transformations include hydrolysis, oxidation and reduction. Specifically, when a prodrug of this invention is administered to a patient, the prodrug may be transformed into a compound of formula (I), thereby imparting the desired pharmacological effect.
• Step 1 involves reacting and aminoheterocycle of the formula (II): Ar,-NH 2 with phenyl chloroformate to form a carbamate compound of the formula (V):
• Step 2 is reacting the carbamate of the formula (V) from step 1 with an aromatic amine of the formula (IV):
• Ar 2 , L, Q and X are as defined hereinabove.
• the compounds of the invention may be prepared by Method A - P as illustrated below.
• the method of preparation will vary depending on the particular compound desired and the proper method chosen will be apparent to one of ordinary skill in the art.
• Desired intermediate aminoheterocycles (2), of the formula II can be prepared by methods known in the art and described in the literature. The method used to produce an aminoheterocycle of formula II will depend on the nature of the desired heterocycle. Some general methods are illustrated in the schemes below. Compounds OCN-Ar 2 -L-Q or NH 2 -Ar 2 -L-Q may be commercially available, or may be prepared by methods known to those skilled in the art. Illustrative examples are contained in the Synthetic Procedures section below.
• Methyl 5-alkyl-3-aminothiophene-2-carboxylates (2) can be prepared from the base catalyzed condensation of methyl thioglycolate (3) and 2-alkyl-2-chloroacrylonitrile (4).
• the preferred base is sodium methoxide.
• the preferred solvent is methanol and the preferred reaction temperatures are between 50-90° C. Purification of the product can be accomplished by recrystallization, distillation or silica gel chromatography.
• This 3-aminothiophene (2) can be treated with phenyl chloroformate in the presence of a base.
• the preferred base is pyridine or triethylamine and the preferred solvent is THF.
• the resultant thiophene phenyl carbamate (5) is reacted with an aromatic amine (6) in DMSO with a base, such as triethylamine, to give the urea product (1) which can be purified by recrystallization or silica gel chromatography.
• a base such as triethylamine
• 3-Aminothiophene (2) is dissolved in methylene chloride and aqueous sodium bicarbonate and cooled to 0° C. Phosgene is added and the thiophene isocyanate (7) is separated from the aqueous layer, dried and reacted with an aromatic amine (6) and a base, such as triethylamine, in a non-protic solvent, such as THF, to give the urea product (1).
• a base such as triethylamine
• Aromatic amine (6) is dissolved in methylene chloride and aqueous sodium bicarbonate and cooled to 0° C. Phosgene is added and the aromatic isocyanate (8) is separated from the aqueous layer, dried and reacted with the thiophene amine (2) to give the urea product (1).
• 2-Methylcarbamoyl-5-alkyl-3-aminothiophenes (13) can be prepared from methyl 5- alkyl-3-aminothiophene-2-carboxylates (2) by reacting the amino group with benzyl chloroformate in a non-protic solvent, such as toluene, and a base, such as sodium carbonate.
• a non-protic solvent such as toluene
• a base such as sodium carbonate.
• the resultant methyl 3-(N-carbobenzyloxyamino)-5-alkyl-thiophene-2- carboxylate (11) can be treated with methylamine and NaCN in a protic solvent, such as methanol, in a sealed vessel at elevated temperatures. The preferred temperatures are between 50-90° C.
• l-[2-(Aminomethyl)-5-alkyl-3-thienyl]-3-[aryl]-urea (15) can be prepared by treatment of l-[2-carbamoyl-5-alkyl-3-thienyl]-3-[aryl]-urea (16), which can be prepared according to Method D by replacing methy lamine with ammonia, with a hydride reducing agent, such as borane in THF in a non-protic solvent, such as THF, at elevated temperatures, such as between 50-90° C, and purification by silica gel chromatography.
• a hydride reducing agent such as borane in THF in a non-protic solvent, such as THF
• An amide (16) can be prepared by coupling of this amine with an N-protected glycine, such as N-carbo-tert-butoxyglycine (17), with standard peptide forming reagents, such as dicyclohexylcarbodiimide and hydroxybenzotriazole, in a non-protic solvent, such as THF, and purification of the product with silica gel chromatography.
• N-protected glycine such as N-carbo-tert-butoxyglycine (17)
• standard peptide forming reagents such as dicyclohexylcarbodiimide and hydroxybenzotriazole
• Formation of the N-acetyl product (14) can be accomplished by treatment of (16) with acid to furnish amine (17) and subsequent reaction with an acylating reagent, such as acetyl chloride or acetic anhydride, in a non-protic solvent, such as THF, and purification by silica gel chromatography.
• an acylating reagent such as acetyl chloride or acetic anhydride
• 5-Alkyl-furan-2-carboxylate (19) can be prepared by treatment of 2-alkyl-furan (20) with a strong base, such as butyl lithium, in a non-protic solvent, such as THF, at temperatures -78 - 0° C and quenching with carbon dioxide.
• a strong base such as butyl lithium
• a non-protic solvent such as THF
• Methyl 5-alkyl-3- amino-furan-2-carboxylate (21) can be prepared by treatment of 5-alkyl-furan-2- carboxylate (19) with a strong base, such as butyl lithium, in a non-protic solvent, such as THF, at temperatures -78 - 0° C and quenching with tosylazide.
• the carboxylic acid can be esterified with TMSCHN 2 in methanol to give methyl 5- alkyl-3-amino-furan-2-carboxylate (22).
• Urea formation with this amine can be accomplished by Method A, B or C, as described above, to provide l-[2- carbomethoxy-5-alkyl-3-furyl]-3-[aryl]-urea (18).
• Methyl 5-alkyl-pyrrole-2-carboxylate (24) can be prepared by treatment of methyl pyrrole-2-carboxylate (25) with a Lewis acid, such as A1C1 3 , in a non-protic solvent, such as dichloromethane, and a chloroalkane, such as 2-chloro-2- methy lproprane.
• a Lewis acid such as A1C1 3
• a non-protic solvent such as dichloromethane
• a chloroalkane such as 2-chloro-2- methy lproprane.
• Nitration of this product (24) can be accomplished with fuming nitric acid to afford methyl 5-alkyl-3-nitropyrrole-2-carboxylate (26) which upon hydrogenation with a palladium catalyst in a protic solvent, such as methanol, and purification with silica gel chromatography would afford methyl 5-alkyl-3- aminopyrrole-2-carboxylate (27).
• Urea formation with this amine by Method A, B or C, as described above, would furnish l-[2-carbomethoxy-5-alkyl-3-pyrrolyl]-3- [aryl]-urea (23).
• 5-Alkyl-3-nitropyrrole-2-carboxylate (29) can be prepared from methyl 5-alkyl-3- nitropyrrole-2-carboxylate (26), as prepared above, by treatment with alkali, such as sodium hydroxide, in solvent mixtures, such as THF, methanol and water, at temperatures between 50-90° C. Purification of the product can be accomplished by trituration or silica gel chromatography.
• alkali such as sodium hydroxide
• Conversion of 5-alkyl-3-nitropyrrole-2- carboxylate (29) to 2-methylcarbamoyl-5-alkyl-3-nitropyrrole (30) can be accomplished by treatment with methy lamine and amide forming reagents, such as EDCI, in non-protic solvents, such as THF and DMF.
• 2-Methylcarbamoyl-5-alkyl- 3-aminopyrrole (31) can be prepared by reduction of the nitro group by hydrogen in the presence of a palladium catalyst in a non-protic solvent, such as ethyl acetate.
• Methyl 1 -methy l-5-alkyl-3-nitropyrrole-2-carboxylate (33) can be prepared by treating methyl 5-alkyl-3-nitropyrrole-2-carboxylate (26) with alkali, such as NaOH, in a mixture of a non-protic solvent, such as methylene chloride, and water with a phase transfer catalyst, such as benzyltributylammonium bromide, and a methylating agent, such as dimethyl sulfate.
• alkali such as NaOH
• a phase transfer catalyst such as benzyltributylammonium bromide
• a methylating agent such as dimethyl sulfate.
• the preferred temperature is between 0-25° C.
• Purification of methyl l-methyl-5-alkyl-3-nitropyrrole-2-carboxylate (33) can be accomplished by silica gel chromatography.
• Reduction of the nitro group can be completed with hydrogen and a palladium catalyst, such as palladium on carbon.
• Urea formation with this amine (34) can be accomplished by Method A, B or C, as described above, to furnish l-[l-methyl-2-carbomethoxy-5-alkyl-3-pyrrolyl]-3- [aryl]-urea (32).
• 2-Carbomethoxy-5-tert-butyl-3-aminothiophene (36) can be prepared by the condensation of methyl cyanoacetate (37), 3,3-dimethylbutraldehyde (38) and sulfur in a non-protic base, such as DMF, and a base, such as triethylamine. Purification of the product can be accomplished with silica gel chromatography. Urea formation with this amine (36) can be accomplished as described by Method A, B or C, as described above, to furnish l-[2-carbomethoxy-5-tert-butyl-3-thienyl]-3-[aryl]-urea (35).
• 4-Amino-l-naphthol hydrochloride (40) can be neutralized with a base, such as n- butyl lithium, in a non-protic solvent , such as THF, and reacted with di-tert-butyl dicarbonate ((BOC) 2 O) at temperatures between -78 - 25° C.
• the product, 4-tert- butyloxycarbonylamino-1-naphthol (41) can be alkylated with 4-(2- chloroethyl)mo ⁇ holine hydrochloride in a non-protic solvent, such as acetonitrile, with a base, such as powdered potassium carbonate, at temperatures between 60-80° C.
• 4-tert-Butyloxycarbonylamino-l-naphthol (41) can be alkylated with 4- chloromethylpyridine hydrochloride in a non-protic solvent, such as acetonitrile, with a base, such as powdered potassium carbonate, at temperatures between 60-80° C.
• a non-protic solvent such as acetonitrile
• a base such as powdered potassium carbonate
• Removal of the BOC-protecting group can be accomplished with HCl in a non- protic solvent, such as dioxane, to provide l-amino-4-(pyridin-4-yl- methoxy)naphthalene (43) as the hydrochloride salt.
• a non- protic solvent such as dioxane
• 4-tert-Butyloxycarbonylamino-l-naphthol (41) can be alkylated with l-bromo-2- chloroethane in a non-protic solvent, such as acetonitrile, with a base, such as powdered potassium carbonate, at temperatures between 60-80° C.
• a non-protic solvent such as acetonitrile
• a base such as powdered potassium carbonate
• Conversion of 4-tert- butyloxycarbonylamino-l-(2-chloroethoxy)naphthalene (46) to 4-tert- butyloxycarbonylamino-l-(2-iodooethoxy)naphthalene (47) can be accomplished with the Nal in a non-protic solvent, such as acetone, at elevated temperatures.
• a non-protic solvent such as acetone
• Treatment of (47) with thiomo ⁇ holine in a non-protic solvent, such as DMF, and a base, such as di-wo-propyl-ethylamine (DIPEA), at room temperature can provide 4-tert-buty loxycarbony lamino- 1 -(2-(thiomo ⁇ holin-4-y l)ethoxy )naphthalene (48) .
• a non-protic solvent such as DMF
• DIPEA di-wo-propyl-ethylamine
• Oxidation of the thiomo ⁇ holine to yield 4-tert-buty loxycarbonylamino-l-(2-(l-oxo- thiomo ⁇ holin-4-yl)ethoxy)naphthalene (49) can be accomplished with sodium periodate in a protic solvent, such as ethanol, at temperatures between 0-25° C. Purification of the product can be performed by silica gel chromatography.
• Removal of the BOC-protecting group of (49) can be executed with trifluoroacetic acid in a non-protic solvent, such as methylene chloride, to furnish l-amino-4-(2-(l-oxo- thiomo ⁇ holin-4-yl)ethoxy)naphthalene (45) .
• a non-protic solvent such as methylene chloride
• 4-Amino-l-naphthol hydrochloride (40) can be neutralized with a base, such as aqueous sodium bicarbonate, in a non-protic solvent , such as ethyl acetate, and reacted 3,4-dimethoxybenzyl alcohol, triphenyl phosphine and diethyl azodicarboxylate (DEADC) in a non-protic solvent, such as THF, at temperatures between 0-25° C.
• a base such as aqueous sodium bicarbonate
• a non-protic solvent such as ethyl acetate
• DEADC diethyl azodicarboxylate
• Purification of l-amino-4-(3,4- dimethoxyphenyl)methoxy)naphthalene (50) can be performed by silica gel chromatography.
• Tetrahydro-2-(2-propynyloxy)-2H-pyran can be treated with a strong base, such as /.-butyl lithium in a non-protic solvent, such as THF, at temperatures between -78-25° C and quenched with tributyltin chloride to furnish tributyltin derivative (53).
• a strong base such as /.-butyl lithium in a non-protic solvent, such as THF
• the compounds of the invention effectively block inflammatory cytokine production from cells.
• the inhibition of cytokine production is an attractive means for preventing and treating a variety of disorders associated with excess cytokine production, e.g., diseases and pathological conditions involving inflammation.
• the compounds of the invention are useful for the treatment of such conditions. These encompass chronic inflammatory diseases including, but not limited to, osteoarthritis, multiple sclerosis, Guillain-Barre syndrome, Crohn's disease, ulcerative colitis, psoriasis, graft versus host disease, systemic lupus erythematosus and insulin- dependent diabetes mellitus.
• the compounds of the invention can also be used to treat other disorders associated with the activity of elevated levels of proinflammatory cytokines such as responses to various infectious agents and a number of diseases of autoimmunity such as rheumatoid arthritis, toxic shock syndrome, diabetes and inflammatory bowel diseases unrelated to those listed above are discussed in the Background of the Invention.
• the compounds of the invention being inhibitors of cytokine production are expected to block inducible cyclooxygenase (COX-2) expression.
• COX-2 expression has been shown to be increased by cytokines and it is believed to be the isoform of cyclooxygenase responsible for inflammation (M.K. O'Banion et al. , Proc. Natl. Acad. Sci. U.S.A, 1992, 89, 4888.)
• the present novel compounds would be expected to exhibit efficacy against those disorders currently treated with COX inhibitors such as the familiar NSAIDs. These disorders include acute and chronic pain as well as symptoms of inflammation and cardiovascular disease.
• the compounds of the invention may be useful in the treatment of diseases mediated predominantly by neutrophils such as stroke and myocardial infarction, alone or following thrombolytic therapy, thermal injury, adult respiratory distress syndrome (ARDS), multiple organ injury secondary to trauma, acute glomerulonephritis, dermatoses with acute inflammatory components, acute purulent meningitis or other central nervous system disorders, hemodialysis, leukopherisis, granulocyte transfusion associated syndromes, and necrotizing entrerocolitis.
• diseases mediated predominantly by neutrophils such as stroke and myocardial infarction, alone or following thrombolytic therapy, thermal injury, adult respiratory distress syndrome (ARDS), multiple organ injury secondary to trauma, acute glomerulonephritis, dermatoses with acute inflammatory components, acute purulent meningitis or other central nervous system disorders, hemodialysis, leukopherisis, granulocyte transfusion associated syndromes, and necrotizing entrerocolitis.
• ARDS adult respiratory distress syndrome
• the compounds of the invention may be administered in any conventional dosage form in any conventional manner.
• Routes of administration include, but are not limited to, intravenously, intramuscularly, subcutaneously, intrasynovially, by infusion, sublingually, transdermally, orally, topically or by inhalation.
• the preferred modes of administration are oral and intravenous.
• the compounds of this invention may be administered alone or in combination with adjuvants that enhance stability of the inhibitors, facilitate administration of pharmaceutic compositions containing them in certain embodiments, provide increased dissolution or dispersion, increase inhibitory activity, provide adjunct therapy, and the like, including other active ingredients.
• combination therapies utilize lower dosages of the conventional therapeutics, thus avoiding possible toxicity and adverse side effects incurred when those agents are used as monotherapies.
• Compounds of the invention may be physically combined with the conventional therapeutics or other adjuvants into a single pharmaceutical composition.
• the compounds may then be administered together in a single dosage form.
• the pharmaceutical compositions comprising such combinations of compounds contain at least about 5%, but more preferably at least about 20%, of a compound of formula (I) (w/w) or a combination thereof.
• the optimum percentage (w/w) of a compound of formula(I) may vary and is within the purview of those skilled in the art.
• the compounds may be administered separately (either serially or in parallel). Separate dosing allows for greater flexibility in the dosing regime.
• dosage forms of the compounds of this invention include pharmaceutically acceptable carriers and adjuvants known to those of ordinary skill in the art.
• carriers and adjuvants include, for example, ion exchangers, alumina, aluminum stearate, lecithin, serum proteins, buffer substances, water, salts or electrolytes and cellulose-based substances.
• Preferred dosage forms include, tablet, capsule, caplet, liquid, solution, suspension, emulsion, lozenges, syrup, reconstitutable powder, granule, suppository and transdermal patch. Methods for preparing such dosage forms are known (see, for example, H.C. Ansel and N.G.
• Dosage levels and requirements are well-recognized in the art and may be selected by those of ordinary skill in the art from available methods and techniques suitable for a particular patient. In some embodiments, dosage levels range from about 10-1000 mg/dose for a 70 kg patient. Although one dose per day may be sufficient, up to 5 doses per day may be given. For oral doses, up to 2000 mg/day may be required. As the skilled artisan will appreciate, lower or higher doses may be required depending on particular factors. For instance, specific dosage and treatment regimens will depend on factors such as the patient's general health profile, the severity and course of the patient's disorder or disposition thereto, and the judgment of the treating physician.
• the inhibition of cytokine production can be observed by measuring inhibition of TNF ⁇ in lipopolysaccharide stimulated THP cells. All cells and reagents are diluted in RPMI 1640 with phenol red and L-glutamine, supplemented with additional L-glutamine (total: 4 mM), penicillin and streptomycin (50 units/ml each) and fetal bovine serum (FBS, 3 %) (GIBCO, all cone, final). Assay is performed under sterile conditions; only test compound preparation is nonsterile. Initial stock solutions are made in DMSO followed by dilution into RPMI 1640 2-fold higher than the desired final assay concentration. Confluent THP.
• l cells (2xl0 6 cells/ml, final cone; American Type Culture Company, Rockville, MD) are added to 96 well polypropylene round bottomed culture plates (Costar 3790; sterile) containing 125 ⁇ l test compound (2 fold concentrated) or DMSO vehicle (controls, blanks). DMSO concentration should not exceed 0.2% final.
• Cell mixture is allowed to preincubate for 30 min, 37°C, 5% CO 2 prior to stimulation with lipopolysaccharide (LPS; 1 ⁇ g/ml final; Siga L-2630, from E.coli serotype 0111.B4; stored as 1 mg/ml stock in endotoxin screened distilled H 2 O at -80°C).
• LPS lipopolysaccharide
• Blanks receive H 2 O vehicle; final incubation volume is 250 ⁇ l. Overnight incubation (18 - 24 hr) proceeds as described above. Assay is to be terminated by centrifuging plates 5 min, room temperature, 1600 rpra (400 x g); supernatants are then transferred to clean 96 well plates and stored -80°C until analyzed for human TNF ⁇ by a commercially available ELISA kit (Biosource #KHC3015, Camarillo, CA). Data is analyzed by non-linear regression (Hill equation) to generate a dose response curve using SAS Software System (SAS institute, Inc. , Cary, NC). The calculated IC50 value is the concentration of the test compound that caused a 50% decrease in the maximal TNF ⁇ production.
• Preferred compounds of the invention will have an activity wherein the IC 50 ⁇ 10 ⁇ M in this assay.

Landscapes

• Chemical & Material Sciences (AREA)
• Organic Chemistry (AREA)
• Health & Medical Sciences (AREA)
• Life Sciences & Earth Sciences (AREA)
• Bioinformatics & Cheminformatics (AREA)
• Veterinary Medicine (AREA)
• Chemical Kinetics & Catalysis (AREA)
• General Chemical & Material Sciences (AREA)
• Medicinal Chemistry (AREA)
• Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
• Public Health (AREA)
• Pharmacology & Pharmacy (AREA)
• Engineering & Computer Science (AREA)
• Animal Behavior & Ethology (AREA)
• General Health & Medical Sciences (AREA)
• Rheumatology (AREA)
• Physical Education & Sports Medicine (AREA)
• Diabetes (AREA)
• Immunology (AREA)
• Biomedical Technology (AREA)
• Orthopedic Medicine & Surgery (AREA)
• Neurosurgery (AREA)
• Neurology (AREA)
• Cardiology (AREA)
• Heart & Thoracic Surgery (AREA)
• Hematology (AREA)
• Dermatology (AREA)
• Urology & Nephrology (AREA)
• Pain & Pain Management (AREA)
• Emergency Medicine (AREA)
• Hospice & Palliative Care (AREA)
• Psychiatry (AREA)
• Pulmonology (AREA)
• Endocrinology (AREA)
• Obesity (AREA)
• Vascular Medicine (AREA)
• Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
• Heterocyclic Compounds Containing Sulfur Atoms (AREA)
• Furan Compounds (AREA)
• Pyrrole Compounds (AREA)

Priority Applications (6)

Applications Claiming Priority (2)

Publications (1)

Family

ID=22413056

Family Applications (1)

Country Status (9)

Cited By (23)

Families Citing this family (23)

Citations (7)

Family Cites Families (46)

• 2000
  • 2000-01-31 DE DE60023853T patent/DE60023853T2/de not_active Expired - Lifetime
  • 2000-01-31 ES ES00909993T patent/ES2251360T3/es not_active Expired - Lifetime
  • 2000-01-31 AT AT00909993T patent/ATE309237T1/de active
  • 2000-01-31 WO PCT/US2000/002008 patent/WO2000055152A1/en active IP Right Grant
  • 2000-01-31 CA CA002361998A patent/CA2361998C/en not_active Expired - Fee Related
  • 2000-01-31 MX MXPA01009077A patent/MXPA01009077A/es not_active IP Right Cessation
  • 2000-01-31 JP JP2000605581A patent/JP2002539206A/ja active Pending
  • 2000-01-31 EP EP00909993A patent/EP1163236B1/en not_active Expired - Lifetime
  • 2000-02-14 US US09/503,385 patent/US6297381B1/en not_active Expired - Lifetime
  • 2000-11-20 US US09/716,351 patent/US6476023B1/en not_active Expired - Lifetime

Patent Citations (7)

Also Published As

Similar Documents

Legal Events